viernes, 11 de marzo de 2022

Ribociclib plus endocrine therapy offers survival benefit for postmenopausal patients with metastatic breast cancer

Ribociclib plus endocrine therapy offers survival benefit for postmenopausal patients with metastatic breast cancer

No hay comentarios:

Publicar un comentario